Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHPA saw palmetto claim

This article was originally published in The Tan Sheet

Executive Summary

"There is no basis to conclude that consumers will improperly use" supplements containing saw palmetto if they feature a health claim, AHPA maintains in amicus brief filed May 28. FDA concern that men may self-medicate with saw palmetto and delay diagnosis of other conditions such as cancer "could be fully addressed through a requirement that the saw palmetto health claim be accompanied by information about the need for regular prostate exams," group states. Adding such language "would benefit, not harm, the public health," AHPA adds. Emord & Associates appealed lower court ruling upholding FDA's decision to deny claim in May (1"The Tan Sheet" May 26, 2003, p. 13)...
Advertisement

Related Content

Health Claims Law Includes Effect On Existing Disease – Saw Palmetto Appeal
Health Claims Law Includes Effect On Existing Disease – Saw Palmetto Appeal

Topics

Advertisement
UsernamePublicRestriction

Register

PS095539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel